Search Results - "Lacina, Ladislav"

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry by Zurkova, Monika, Kriegova, Eva, Kolek, Vitezslav, Lostakova, Vladimira, Sterclova, Martina, Bartos, Vladimir, Doubkova, Martina, Binkova, Ilona, Svoboda, Michal, Strenkova, Jana, Janotova, Marketa, Plackova, Martina, Lacina, Ladislav, Rihak, Vladimir, Petrik, Frantisek, Lisa, Pavlina, Bittenglova, Radka, Tyl, Richard, Ondrejka, Gustav, Suldova, Hana, Lnenicka, Jaroslav, Psikalova, Jana, Snizek, Tomas, Homolka, Jiri, Kralova, Renata, Kervitzer, Jan, Vasakova, Martina

“…Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the…”
Get full text

EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis by Doubková, Martina, Švancara, Jan, Svoboda, Michal, Šterclová, Martina, Bartoš, Vladimír, Plačková, Martina, Lacina, Ladislav, Žurková, Monika, Binková, Ilona, Bittenglová, Radka, Lošťáková, Vladimíra, Merta, Zdeněk, Šišková, Lenka, Tyl, Richard, Lisá, Pavlína, Šuldová, Hana, Petřík, František, Pšikalová, Jana, Řihák, Vladimír, Snížek, Tomáš, Reiterer, Pavel, Homolka, Jiří, Musilová, Pavlína, Lněnička, Jaroslav, Palúch, Peter, Hrdina, Roman, Králová, Renata, Hortvíková, Hana, Strenková, Jana, Vašáková, Martina

“…Prognostic factors of idiopathic pulmonary fibrosis (IPF) currently recognized include changes in vital capacity and radiologic findings. However, most of the…”
Get more information

Adherence to the ISHLT Protocol for the Referral of Patients with Idiopathic Pulmonary Fibrosis to the Transplantation Center among of Czech Centers for Interstitial Lung Diseases by Sterclova, Martina, Doubkova, Martina, Sykorova, Lubica, Bartos, Vladimir, Zurkova, Monika, Lostakova, Vladimira, Mokosova, Radka, Plackova, Martina, Lacina, Ladislav, Cimrova, Michaela, Bittenglova, Radka, Lisa, Pavlina, Musilova, Pavla, Dolezal, Daniel, Psikalova, Jana, Ovesna, Petra, Koziar Vasakova, Martina

“…There are limited data on referral rates and the number of patients with idiopathic pulmonary fibrosis (IPF) who are eligible for lung transplantation. The aim…”
Get full text

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry by Štefániková, Marianna, Doubková, Martina, Ovesná, Petra, Šterclová, Martina, Lacina, Ladislav, Žurková, Monika, Plačková, Martina, Bartoš, Vladimír, Janíčková, Ivana, Bittenglová, Radka, Anton, Jan, Sýkorová, Ľubica, Lošťáková, Vladimíra, Musilová, Pavlína, Šuldová, Hana, Mokošová, Radka, Didyk, Jurij, Šišáková, Lenka, Lisá, Pavlína, Lněnička, Jaroslav, Dařičková, Hana, Doležel, Daniel, Pšikalová, Jana, Tyl, Richard, Králová, Renata, Vašáková, Martina Koziar

“…The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic…”
Get full text

The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis by Tran, Tanja, Šterclová, Martina, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Müller, Veronika, Hájková, Marta, Kramer, Mordechai R, Jovanović, Dragana, Tekavec-Trkanjec, Jasna, Studnicka, Michael, Stoeva, Natalia, Hejduk, Karel, Dušek, Ladislav, Suissa, Samy, Vašáková, Martina

“…Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of…”
Get full text

Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study by Jovanovic, Dragana M, Šterclová, Martina, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Müller, Veronika, Hájková, Marta, Studnicka, Michael, Tekavec-Trkanjec, Jasna, Littnerová, Simona, Vašáková, Martina

“…Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical…”
Get full text

The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry by Gregor, Jakub, Adir, Yochai, Šterclová, Martina, Mogulkoc, Nesrin, Kramer, Mordechai R., Doubková, Martina, Plačková, Martina, Müller, Veronika, Studnicka, Michael, Žurková, Monika, Lacina, Ladislav, Lewandowska, Katarzyna, Bartoš, Vladimír, Ovesná, Petra, Májek, Ondřej, Koziar Vašáková, Martina

“…[Display omitted] Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch…”
Get full text

Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry by Doubková, Martina, Uher, Michal, Bartoš, Vladimír, Šterclová, Martina, Lacina, Ladislav, Lošťáková, Vladimíra, Binková, Ilona, Plačková, Martina, Žurková, Monika, Bittenglová, Radka, Pšikalová, Jana, Šišková, Lenka, Lisá, Pavlína, Petřík, František, Polák, Jaroslav, Řihák, Vladimír, Skřičková, Jana, Vašáková, Martina

“…Idiopathic pulmonary fibrosis (IPF) is a rare, progressive and usually fatal form of idiopathic interstitial pneumonia. IPF is characterized by failure of…”
Get more information